Integrase Deficient Lentiviral Vector: Prospects for Safe Clinical Applications

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 Aug 18

PMID 35979475

Authors

Chee-Hong Takahiro Yew

Narmatha Gurumoorthy

Fazlina Nordin

Gee Jun Tye

Wan Safwani Wan Kamarul Zaman

Jun Jie Tan

Min Hwei Ng

Affiliations

Soon will be listed here.

Abstract

HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic materials into the targeted cells among many viral vectors. Genetic material transduced by lentiviral vector is integrated into the cell genome to introduce new functions, repair defective cell metabolism, and stimulate certain cell functions. Various measures have been administered in different generations of lentiviral vector systems to reduce the vector's replicating capabilities. Despite numerous demonstrations of an excellent safety profile of integrative lentiviral vectors, the precautionary approach has prompted the development of integrase-deficient versions of these vectors. The generation of integrase-deficient lentiviral vectors by abrogating integrase activity in lentiviral vector systems reduces the rate of transgenes integration into host genomes. With this feature, the integrase-deficient lentiviral vector is advantageous for therapeutic implementation and widens its clinical applications. This short review delineates the biology of HIV-1-erived lentiviral vector, generation of integrase-deficient lentiviral vector, recent studies involving integrase-deficient lentiviral vectors, limitations, and prospects for neoteric clinical use.

Citing Articles

Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.

Azeez S, Hamad R, Hamad B, Shekha M, Bergsten P Front Genome Ed. 2024; 6:1509924.

PMID: 39726634 PMC: 11669675. DOI: 10.3389/fgeed.2024.1509924.

Prospects for gene therapy in polycystic kidney disease.

Chakraborty A, Yu A Curr Opin Nephrol Hypertens. 2024; 34(1):121-127.

PMID: 39499052 PMC: 11606769. DOI: 10.1097/MNH.0000000000001030.

Emerging trends in virus and virus-like particle gene therapy delivery to the brain.

Mandalawatta H, Rajendra K, Fairfax K, Hewitt A Mol Ther Nucleic Acids. 2024; 35(3):102280.

PMID: 39206077 PMC: 11350507. DOI: 10.1016/j.omtn.2024.102280.

Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems.

Beraza-Millor M, Rodriguez-Castejon J, Del Pozo-Rodriguez A, Rodriguez-Gascon A, Solinis M BioDrugs. 2024; 38(5):657-680.

PMID: 39177875 PMC: 11358353. DOI: 10.1007/s40259-024-00674-1.

Engineering strategies to safely drive CAR T-cells into the future.

Rossi M, Breman E Front Immunol. 2024; 15:1411393.

PMID: 38962002 PMC: 11219585. DOI: 10.3389/fimmu.2024.1411393.

References

Merlin S, Follenzi A . Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors. Mol Ther Methods Clin Dev. 2019; 12:223-232. PMC: 6365353. DOI: 10.1016/j.omtm.2018.12.013. View

Hamid F, Kim J, Shin C . Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update. AIDS Res Ther. 2017; 14(1):9. PMC: 5314604. DOI: 10.1186/s12981-016-0127-6. View

Cornu T, Cathomen T . Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther. 2007; 15(12):2107-13. DOI: 10.1038/sj.mt.6300345. View

Zufferey R, Dull T, Mandel R, Bukovsky A, Quiroz D, Naldini L . Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12):9873-80. PMC: 110499. DOI: 10.1128/JVI.72.12.9873-9880.1998. View

. Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016; 43(3):203-22. PMC: 4924471. DOI: 10.1159/000445852. View

Chen S, Sun J, Chen B, Lin S, Chang H, Collins S . Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. Int J Mol Sci. 2020; 21(4). PMC: 7073086. DOI: 10.3390/ijms21041433. View

Nienhuis A, Nathwani A, Davidoff A . Gene Therapy for Hemophilia. Mol Ther. 2017; 25(5):1163-1167. PMC: 5417837. DOI: 10.1016/j.ymthe.2017.03.033. View

Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P . HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 2000; 101(2):173-85. DOI: 10.1016/S0092-8674(00)80828-4. View

Petrillo C, Thorne L, Unali G, Schiroli G, Giordano A, Piras F . Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell. 2018; 23(6):820-832.e9. PMC: 6292841. DOI: 10.1016/j.stem.2018.10.008. View

10.

Wunderlich S, Haase A, Merkert S, Beier J, Schwanke K, Schambach A . Induction of pluripotent stem cells from a cynomolgus monkey using a polycistronic simian immunodeficiency virus-based vector, differentiation toward functional cardiomyocytes, and generation of stably expressing reporter lines. Cell Reprogram. 2012; 14(6):471-84. PMC: 4277039. DOI: 10.1089/cell.2012.0041. View

11.

Senis E, Mosteiro L, Wilkening S, Wiedtke E, Nowrouzi A, Afzal S . AAVvector-mediated in vivo reprogramming into pluripotency. Nat Commun. 2018; 9(1):2651. PMC: 6037684. DOI: 10.1038/s41467-018-05059-x. View

12.

Vink C, Gaspar H, Gabriel R, Schmidt M, McIvor R, Thrasher A . Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther. 2009; 17(7):1197-204. PMC: 2835211. DOI: 10.1038/mt.2009.94. View

13.

Maertens G, Engelman A, Cherepanov P . Structure and function of retroviral integrase. Nat Rev Microbiol. 2021; 20(1):20-34. PMC: 8671357. DOI: 10.1038/s41579-021-00586-9. View

14.

Tagliafierro L, Zamora M, Chiba-Falek O . Multiplication of the SNCA locus exacerbates neuronal nuclear aging. Hum Mol Genet. 2018; 28(3):407-421. PMC: 6337700. DOI: 10.1093/hmg/ddy355. View

15.

Aravantinou-Fatorou K, Thomaidou D . In Vitro Direct Reprogramming of Mouse and Human Astrocytes to Induced Neurons. Methods Mol Biol. 2020; 2155:41-61. DOI: 10.1007/978-1-0716-0655-1_4. View

16.

Slon-Campos J, Poggianella M, Zentilin L, Burrone O . Use of Adeno-associated viral vectors to improve delivery of a DNA vaccine against dengue virus. J Gen Virol. 2019; 101(1):73-78. DOI: 10.1099/jgv.0.001351. View

17.

Ku M, Authie P, Nevo F, Souque P, Bourgine M, Romano M . Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Commun Biol. 2021; 4(1):713. PMC: 8192903. DOI: 10.1038/s42003-021-02251-6. View

18.

de Solis C, Hosek M, Holehonnur R, Ho A, Banerjee A, Luong J . Adeno-associated viral serotypes differentially transduce inhibitory neurons within the rat amygdala. Brain Res. 2017; 1672:148-162. DOI: 10.1016/j.brainres.2017.07.023. View

19.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

20.

Bona R, Michelini Z, Mazzei C, Gallinaro A, Canitano A, Borghi M . Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Mol Ther Methods Clin Dev. 2021; 23:263-275. PMC: 8526422. DOI: 10.1016/j.omtm.2021.09.011. View